Mymetics Corporation Retains Lazard Bank to Further the Company's Merger, Acquisition and Expansion Activities

NYON, Switzerland, Dec. 10, 2008 (GLOBE NEWSWIRE) -- Mymetics Corporation
(OTCBB:MYMX), announced today that it has retained Lazard as its financial
advisor to provide the company with independent advice on strategic
transactions, tactical acquisitions and other financial matters for the period
2009 to 2011. 

"With the unfailing support of a small group of Swiss investors, we have raised
CHF 32 million over the last 3 years, and thanks to those investors we have
been able to achieve decisive breakthroughs in the development of a
preventative vaccine for HIV/AIDS. Not wishing to remain a single product
company, we acquired a Malaria vaccine using the same delivery system
(virosome) as our HIV/AIDS vaccine," stated Christian J. F. Rochet, President
and CEO of Mymetics, who added, "the advice and the support of Lazard will
enable us to achieve the second phase of our development, which will be
primarily reflected in 2009 through strategic acquisitions and partnerships." 

About Lazard

Lazard, one of the world's preeminent financial advisory and asset management
firms, operates from 41 cities across 24 countries in North America, Europe,
Asia, Australia, Central and South America. With origins dating back to 1848,
the firm provides advice on mergers and acquisitions, restructuring and capital
raising, as well as asset management services to corporations, partnerships,
institutions, governments, and individuals. 

About Mymetics Corporation

Mymetics' corporate objective is to develop vaccines and therapies to prevent
and treat the effects of certain retroviruses and other infectious diseases,
including HIV/AIDS and Malaria. In Q4 2008 Mymetics will commence Phase 1b
Human Clinical trials of their HIV/AIDS preventative vaccine candidate which
showed extremely promising results (see Press Release September 16, 2008) as
well as continuing Mymetics' long term Malaria vaccine in Phase II Human
Clinical trials. Additional applications of Mymetics' research include
potential treatments and/or vaccines for human oncoviral leukemias, multiple
sclerosis, and organ transplantation. Long range growth plans key to Mymetics'
development include acquisitions of prophylactic or therapeutic vaccines
against breast cancer, candidiasis, RSV, malaria and hepatitis. 

The Mymetics Corporation logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=5478 

CONTACT:  Mymetics, Inc.
          North America 
          Anthony G. J. Jessop, Senior Vice President
          1 303 800 6606
          ajessop@mymetics.com